PD-L1 Expression in Triple Negative Breast Cancer

Early phase trials targeting the T-cell inhibitory molecule PD-L1 have shown clinical efficacy in cancer. This study was undertaken to determine whether PD-L1 is overexpressed in triple-negative breast cancer (TNBC) and to investigate the loss of the phosphatase and tensin homolog (PTEN) as a mechan...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Mittendorf, Elizabeth A., Philips, Anne V., Meric-Bernstam, Funda, Qiao, Na, Wu, Yun, Harrington, Susan, Su, Xiaoping, Wang, Ying, Gonzalez-Angulo, Ana M., Akcakanat, Argun, Chawla, Akhil, Curran, Michael, Hwu, Patrick, Sharma, Padmanee, Litton, Jennifer K., Molldrem, Jeffrey J., Alatrash, Gheath
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4000553/
https://ncbi.nlm.nih.gov/pubmed/24764583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-13-0127
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares